Demo Data from EDBT 2026 / reviewers in the wild / expert
Marc C. Nicklaus
dblp:41/1468
· DBLP profile ↗
1ranked-venue papers
0as first author
0since 2021 · last 2020
0000-0002-4775-7030ORCID · verified
Domains — the database's venue-derived domains; a paper can count in several
Applied, interdisciplinary, general and emerging computing · 1
Expertise — from the expertise taxonomy: the topics of the expert's papers under the CCF categories. A weight counts papers with recency: 1 for a paper about the topic, 0.3 when the topic is its context, halved every five years.
| Interdisciplinary, comprehensive, and emerging computing
1 paper |
Bioinformatics and computational biology · 100% |
Topics — the 2 heaviest of 2, each with the papers that count most for it
| Topic | Weight | Papers | Last | Evidence papers |
|---|---|---|---|---|
Bioinformatics and computational biology › drug discovery
computational drug discovery |
0.4 | 1 | 2020 | AntiHIV-Pred: web-resource for in silico prediction of anti-HIV/AIDS activity · Bioinform. 2020 |
Bioinformatics and computational biology › molecular property prediction
quantitative structure-activity relationship modeling |
0.4 | 1 | 2020 | AntiHIV-Pred: web-resource for in silico prediction of anti-HIV/AIDS activity · Bioinform. 2020 |
Methods — techniques the papers use, named apart from their topics
regression · 0.4classification · 0.4PASS · 0.4GUSAR · 0.4
| Year | Publication | Venue | Position |
|---|---|---|---|
| 2020 | AntiHIV-Pred: web-resource for in silico prediction of anti-HIV/AIDS activityabstractMOTIVATION: Identification of new molecules promising for treatment of HIV-infection and HIV-associated disorders remains an important task in order to provide safer and more effective therapies. Utilization of prior knowledge by application of computer-aided drug discovery approaches reduces time and financial expenses and increases the chances of positive results in anti-HIV R&D. To provide the scientific community with a tool that allows estimating of potential agents for treatment of HIV-infection and its comorbidities, we have created a freely-available web-resource for prediction of relevant biological activities based on the structural formulae of drug-like molecules. RESULTS: Over 50 000 experimental records for anti-retroviral agents from ChEMBL database were extracted for creating the training sets. After careful examination, about seven thousand molecules inhibiting five HIV-1 proteins were used to develop regression and classification models with the GUSAR software. The average values of R2 = 0.95 and Q2 = 0.72 in validation procedure demonstrated the reasonable accuracy and predictivity of the obtained (Q)SAR models. Prediction of 81 biological activities associated with the treatment of HIV-associated comorbidities with 92% mean accuracy was realized using the PASS program. AVAILABILITY AND IMPLEMENTATION: Freely available on the web at http://www.way2drug.com/hiv/. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online. Leonid A. Stolbov, Dmitry S. Druzhilovskiy, Anastasia V. Rudik, Dmitry Filimonov, Vladimir Poroikov, Marc C. Nicklaus |
Bioinform. | 6 |